ReviewThe lancet. HIV2023
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.
Review in The lancet. HIV, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025Guideline
- Impact of Post-exposure Prophylaxis on Pre-exposure Prophylaxis Initiation Among Men Who Have Sex with Men: A Nested Case-control Study.AIDS and behavior · 2026Article
- Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Role of pharmacists in HIV prophylaxis: a scoping review of pharmacists' services, interventions and outcomes.Journal of the International AIDS Society · 2026Article
- A national, multicenter, retrospective study of human immunodeficiency virus infection-associated lymphoma in China.Clinical and experimental medicine · 2025Article
- Enhancing Emergency Preparedness: A Call to Incorporate Postexposure Prophylaxis in Mass Casualty Protocols.Health science reports · 2025Article
- Implementing the new WHO guidelines on HIV post-exposure prophylaxis: perspectives from five African countries.Journal of the International AIDS Society · 2025Article
- Do we need a regulatory path for HIV post-exposure prophylaxis?Journal of the International AIDS Society · 2025Article
- How plausible is it that PEP would be cost-effective in sub-Saharan Africa?Journal of the International AIDS Society · 2025Article
- Research designs to generate evidence of HIV post-exposure prophylaxis effectiveness for new long-acting agents.Journal of the International AIDS Society · 2025Article
- Physician Attitudes Towards Pharmacist-Prescribed HIV Post-Exposure Prophylaxis (PEP): A Survey of a State Medical Association.Journal of community health · 2025Article
- Article
- The heart of the matter: modeling HIV-associated cardiovascular comorbidities in nonhuman primate models.Frontiers in cellular and infection microbiology · 2025Review
- Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out.Current opinion in HIV and AIDS · 2025Review
- Infection Control in Dentistry in the Post-COVID Era: A Timely Update.International dental journal · 2024Article
- Updated guidelines on HIV post-exposure prophylaxis: continued efforts towards increased accessibility.Journal of the International AIDS Society · 2024Article
- Bloodborne Infections Relevant to Dental Practice.International dental journal · 2024Review
- Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.Pharmaceutics · 2024Review
- Assessment of Needlestick and Sharps Injuries (NSSIs) Amongst Orthopaedic Surgeons in Clinical Practice: A Pan-India Cross-Sectional Study.Indian journal of orthopaedics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Post-exposure prophylaxis (PEP) to prevent HIV acquisition has been recommended for over three decades, but remains underutilised. Over the past decade, clinical trials have established the safety and tolerability of newer PEP regimens, particularly those containing integrase strand transfer inhibitors (INSTIs) combined with a tenofovir and lamivudine or emtricitabine backbone. Several of these regimens were better tolerated than historical controls. Studies in macaques found that shorter courses of PEP with INSTIs were effective, particularly if dosing occurred close to the time of retroviral exposure. Despite the increase in well tolerated options, PEP seems to be underused globally and links to other prevention services are suboptimal. Interventions to increase provider and community awareness of PEP are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.